Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Exiqon Announces 2011 Grant Program for MicroRNA Research

Published: Wednesday, February 02, 2011
Last Updated: Wednesday, February 02, 2011
Bookmark and Share
Company announces the launch of 2011 global research grant program, open to researchers from academic and non-profit institutions.

Exiqon A/S has announced the launch of its 2011 global research grant program, open to researchers from academic and non-profit institutions.

“We at Exiqon aim to support our customers around the world in their daily life at the laboratories and are proud of offering excellent products for identifying the role of microRNAs in developmental and pathological pathways. With this grant program we give them access to a cutting edge technology that cannot be missed in any research institution”, said Executive Vice President Sales & Marketing, Dr. Elisete Pedrollo.

The Exiqon Grant Program has been established with an internal seed funding of $40,000 / €30.000 from which awards will be given to researchers to drive projects enhancing the understanding of how microRNA expression and function relates to normal cellular development, and/or disease-related cellular pathways.

Recipients will use Exiqon Grant Program awards for the purchase of any Exiqon microRNA product or service. Exiqon offers a complete product line for microRNA investigation, including products for RNA isolation, Microarray analysis, qRT-PCR analysis, Northern Blotting, In Situ Hybridization, and Knockdown studies. Exiqon also offers microRNA profiling services for both microarray and qRT-PCR analysis, complete with full sample QC and customized data analysis and reporting.

Researchers are invited to submit an abstract, outlining their research area, project goals, and proposed workflow no later than Monday, 28 February 2011. Award conveyance through the Exiqon Grant Program does not influence, and is not influenced by, any other existing or potential sources of project funding.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Exiqon Secures Funding to Accelerate Growth
Exiqon A/S has announced the issue of a senior secured note in the amount of DKK 40 million (‘Note’).
Thursday, November 12, 2015
Exiqon Launches New LNA™ Antisense Oligonucleotides for RNA Functional Analysis
These new products offer a powerful alternative to existing siRNAs already on the market place.
Tuesday, May 26, 2015
Exiqon Licenses Biomarkers From Aarhus University Hospital
Exiqon A/S has exclusively licensed prostate cancer biomarkers discovered and validated by Aarhus University Hospital, Department of Molecular Medicine (MOMA).
Wednesday, December 03, 2014
Redefining High Risk Patients With Stage II Colon Cancer
microRNA-21 identified as an independent prognostic biomarker.
Friday, September 12, 2014
Exiqon Awarded Global microRNA Research Tools Company of the Year
Company has been recognized as the recipient of the award in light of the excellence that Exiqon has exhibited in the microRNA research space.
Monday, July 08, 2013
Exiqon and Asuragen Sign Agreement for Real-Time PCR Services
The Service Center Agreement allows Asuragen to provide real-time PCR services based on Exiqon’s miRCURY LNA™ Universal RT microRNA PCR products.
Tuesday, June 11, 2013
Exiqon and MultiD Sign Development and Distribution Agreement for microRNA qPCR Analysis Solution
Agreement incorporates a specifically adapted version of the GenEx qPCR analysis software for Exiqon's new microRNA qPCR platform.
Wednesday, May 26, 2010
Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence
ICCB-L will provide the Exiqon LNA™ microRNA Knockdown Library as a screening tool for a new consortium of Harvard-affiliated investigators.
Tuesday, December 01, 2009
Exiqon Expands in US; Sales Headquarters Established
Establishing a US presence will liberate resources at the existing Danish facility to focus on sales opportunities in Europe and Asia.
Thursday, September 14, 2006
Exiqon Appoints President and General Manager of new US Operations
Michael Kallelis will have the overall responsibility for launching and operating Exiqon’s US office to be located in the Boston area.
Friday, January 06, 2006
Exiqon Wins Ernst & Young Entrepeneur of the Year Award
Exiqon selected as winner in the BIOTECH 2005 category.
Tuesday, November 22, 2005
Scientific News
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
New Mechanism to Control Human Viral Infections Discovered
Researchers discover long sought after mechanism in human cells that could help treat diseases caused by viruses.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
RNAi Activated in Response to Influenza
Discovery could lead to better ways of combating serious infections, including Ebola and Zika.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
Transporting Microscopic Cargo Between Human Cells
Scientists have developed a virus-inspired delivery system for material transport between cells.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
Turning Off Asthma Attacks
Researchers discover a critical cellular “off” switch for the inflammatory immune response that causes asthma attacks.
New Strategy May Drop Cancer’s Guard
Scientists eye ways to deconstruct tumors’ protective wall with current diabetes drug.
Scientists Identify Unique Genomic Features in Testicular Cancer
The findings may shed light on factors in other cancers that influence their sensitivity to chemotherapy.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!